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Abstract
Alzheimer’s disease (AD) is an age-associated progressive neurodegenerative disorder with dementia, the exact pathogenic
mechanisms of which remain unknown. We previously reported that homocysteic acid (HA) may be one of the pathological
biomarkers in the brain with AD and that the increased levels of HA may induce the accumulation of intraneuronal amyloid-
beta (Ab) peptides. In this study, we further investigated the pathological role of HA in a mouse model of AD. Four-month-
old prepathological 3xTg-AD mice exhibited higher levels of HA in the hippocampus than did age-matched nontransgenic
mice, suggesting that HA accumulation may precede both Ab and tau pathologies. We then fed 3-month-old 3xTg-AD mice
with vitamin B6-deficient food for 3 weeks to increase the HA levels in the brain. Concomitantly, mice received either saline
or anti-HA antibody intraventricularly via a guide cannula every 3 days during the course of the B6-deficient diet. We found
that mice that received anti-HA antibody significantly resisted cognitive impairment induced by vitamin B6 deficiency and
that AD-related pathological changes in their brains was attenuated compared with the saline-injected control group. A
similar neuroprotective effect was observed in 12-month-old 3xTg-AD mice that received anti-HA antibody injections while
receiving the regular diet. We conclude that increased brain HA triggers memory impairment and that this condition
deteriorates with amyloid and leads to subsequent neurodegeneration in mouse models of AD.
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Introduction
Amyloid plaques and neurofibrillary tangles are the two
pathophysiological hallmarks of Alzheimer’s disease (AD). Intra-
cellular amyloid-beta 42 (Ab42) is increasingly being recognized as
an early pathological trigger that can lead to amyloid plaques and
may even induce neurofibrillary tangles. We previously reported
that homocysteic acid (HA) induces intracellular accumulation of
Ab42 and that the production of a-synuclein in the presence of
methionine results in cell death [1,19].
HA affects the two pathophysiological hallmarks of AD and
may be involved in its etiology. HA is also known as an NMDA
(N-methyl-D-glutamate) receptor agonist [2] and is released under
mental stress from astrocytes by the activation of b-adrenergic
receptors [3]. Also, previous studies have reported HA-induced
neurodegeneration by oxidative stress [4] and mitochondrial
respiration inhibition [5].
On the basis of these HA toxicities, few researchers have studied
the possibility of HA pathogenicity in the onset of AD [6]. In
humans, it is reported that urinary excretion of homocysteine is
much slower than that of mice [7], which suggests that humans
may produce greater HA level than mice, since HA is known to be
produced from homocysteine.
The 3xTg-AD mouse model showed memory impairment at an
early age because of Ab accumulation in neuronal cells [8,9]. In
this study, we studied 3xTg-AD mice to further investigate the role
of HA in the development of AD-related pathologies in the brain.
We observed an increased level of HA in the hippocampus of 4-
month-old 3xTg-AD homozygous mice compared with the level of
age-matched control mice. The brain HA production in the 3xTg-
AD mice was increased by feeding them with a vitamin B6-
deficient diet for 3 weeks. These pathological changes as well as
cognitive impairments were significantly mitigated by concomitant
intracranial injections of anti-HA antibody in these mice. Our
findings suggest that increased HA may partly contribute to the
progression of AD in the mouse model.
Materials and Methods
3xTg-AD mice
The mouse germline used in this study was a kind gift from
Professor F. M. Laferla (University of California, Irvine). The
housing environment (12 h/12 h light/dark cycle) was a germ-free
clean room. Seven 3xTg-AD hemizygous male mice (3 and 7
months old) were studied. Also, four nontransgenic (non-Tg) mice
were studied. The 3xTg-AD mice developed both plaque and
tangle pathology in AD-relevant brain regions. Despite an
equivalent overexpression of the human sAPP and human tau
transgenes, the 3xTg-AD mice developed extracellular As deposits
before tangle formation, consistent with the amyloid cascade
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plasticity, including long-term potentiation, which occurs before
extracellular As deposition and tau pathology but is associated
with intracellular As immunoreactivity. These results support the
view that synaptic dysfunction is a proximal defect in the
pathobiology of AD and precede extracellular plaque formation
and neurofibrillary pathology. As these 3xTg-AD mice phenocopy
critical aspects of AD neuropathology, this model will be useful in
preclinical intervention trials, particularly because the efficacy of
anti-AD compounds in mitigating the neurodegenerative effects
mediated by both signature lesions can be evaluated.
Vitamin B6-Deficient Food
Vitamin B6-deficient food was purchased from Kyudo Ltd.
Nutrient composition will be described further.
Anti-HA Antibody
Anti-HA antibodies were purchased from MoBiTec Co.
(Germany). Polyclonal antisera were raised in rabbits after
immunization with a glutaraldehyde-containing HA conjugate,
following which antibody specificity was determined by perform-
ing ELISA with competition experiments involving HA-G-BSA,
cysteine-G-BSA, and homocysteine-G-BSA (compound cross-
reactivity ratios 1:1, 1:85, and 1:231, respectively).
HA Vaccine
We synthesized a glutaraldehyde-containing HA conjugate
KLH (Keyhole limpet hemocyanin) compound, and mice were
immunized twice by IP route with this compound and BCG(Ba-
cillus Calmette-Gue ´rin). Two weeks later KLH and BCG
immunized mice again. Immunization volume was 20 mL.
Morris Water Maze Test
The apparatus used for Morris water maze task comprised a
circular aluminum tank (1.5 m in diameter) painted white and
filled with water maintained at 26–29uC. The maze was located in
a room containing several simple, visual extramaze cues. To
reduce stress, mice were placed on a platform in both the hidden
and cued versions of the task for 10 s before the first training trial.
Spatial Reference Morris Water Maze Training
Mice were trained to swim to a 14-cm circular clear Plexiglas
platform placed 1.5 cm below the water surface that was invisible
to the mice while swimming. Platform location was randomly
selected for each mouse but was kept constant for that mouse
throughout the training period. In each trial, mouse was placed in
the tank at one of the four designated starting points in a
pseudorandom order. Mice were allowed to search for and escape
to the submerged platform. If a mouse failed to find the platform
within 60 s, it was manually guided towards it and allowed to
remain there for 10 s. Then, each mouse was placed in a holding
cage under a warming lamp for 25 s until the start of the next trial.
To ensure that memory differences were not due to the lack of task
learning, the mice underwent four trials a day for as many days as
required to meet the criterion, which was defined as a ,20-s mean
escape latency before the first probe trial was run. To prevent
overtraining, probe trials were run for each group as soon as they
met the group criterion and stopped after all the groups met the
criterion. Retention of spatial training was assessed 1.5 and 24 h
after the last training trial. Both probe trials consisted of a 60-s free
swim in the pool without the platform. Mice were monitored by a
camera mounted on the ceiling directly above the pool and all
trials were stored on videotape (burnt onto a DVD) for subsequent
analysis. Parameters measured during the probe trial comprised
initial latency time to reach the platform (1).
Immunohistochemistry
Mice were sacrificed by CO2 asphyxiation, and the brains were
rapidly removed and fixed for 48 h in 4% paraformaldehyde.
Sections (50-mm thick) were processed for free-floating immuno-
histochemistry as previously described [8]. Anti-Ab (6E10)-, anti-
APP (22C11)-, and Ab (40/42)-specific antibodies were applied
overnight at 4uC. Sections were developed with diaminobenzidine
(Vector Laboratories) substrate using the avidin–biotin–horserad-
ish peroxidase system (Vector Laboratories). Quantification of Ab
was performed as described previously. Mice were excluded from
the antibody group analysis (behavior and histology) if the
cannulae were found to be placed incorrectly. To obtain the
percentage difference between the antibody- and PBS-treated
tissues (controls), we applied the following formula: number of
pixels in the antibody-treated hippocampus 2 number of pixels in
the PBS-treated hippocampus/number of pixels in the PBS-
treated hippocampus. The number of pixels calculated in each
case is the sum of five readings per mouse averaged across the
entire group.
HA Level Measurement
HA was extracted from mouse brain (hippocampus and cortex)
with trichloroacetic acid. Brains (1.5022.00 g) were isolated from
4-month-old 3xTg-AD homozygous male mice. Mice were killed
by rapid decapitation and their brains were quickly excised and
placed on an ice-cold petri dish. For the gradient high-
performance liquid chromatography (HPLC) method, tissue
samples were weighed and homogenized using a sonicator for
10 s in ice in 4 mL of ice-cold 10% (w/v) trichloroacetic acid per
100 mg tissue (wet weight). HA (4 mg) was added as an internal
standard. For isocratic HPLC, tissue samples were divided into six
aliquots. The samples were homogenized as described above. The
homogenates for isocratic or gradient HPLC were left on ice for
1 h and centrifuged at 20,0006g for 25 min. The supernatant was
washed five times with an equal volume of diethyl ether and the
aqueous phase was maintained. Residual ether was evaporated
under nitrogen at room temperature for 5 min. Immediately
thereafter, 20 mL was injected into the HPLC system.
Urinay HA Level
Urine of the 3xTg-AD male mice (15-month-old) was collected
for 24 h. The urinary HA level was measured according to the
method of the HPLC system.
Ventricular Cannula
Mice were anesthetized as follows: 2-mm-wide incisions were
made in the left hemisphere and a guide cannula was inserted into
the left ventricular space using a Teflon tube (1 mm in diameter).
This operation did not impair learning and memory performance,
and the abilities of the operated mice were similar to those of mice
that did not undergo surgery.
Statistics
Statistical significance was estimated with Student’s t-test and P-
values (p,0.05).
All animals experiments have been done according to the
accepted international guideline methods and Saga Woman Junior
College approved this work according to animal experimental
guideline.
Homocysteic Acid Vaccine
PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8593Results
HA Levels in Mouse Model Brain
We measured HA levels in the brains of 4-month-old 3xTg-AD-
homozygous mice. At this age, mice display an intracellular
accumulation of Ab in the brain regions affected by AD. This
accumulation also appears to be associated with the early memory
deficit exhibited by these mice [9]. As shown in Table 1, HA levels
in the 3xTg-AD mice were significantly (P,0.05) higher than
those in age-matched control mice. This finding indicates that HA
may contribute to the pathology of AD.
We then fed 3-month-old 3xTg-AD mice vitamin B6-deficient
food for 3 weeks to increase HA levels in the brain. The brain HA
levels were significantly increased following the 3-week vitamin
B6-deficient diet (Table 2). Consistent with this result, the B6-
deficient group exhibited memory impairment compared with the
control group (the normal feeding group exhibited good memory
performance; data not shown here).
To further examine the role of HA in the pathogenesis of AD,
we administered anti-HA antibody intracranially through guide
cannula during the course of the vitamin B6-deficient diet. Anti-
HA antibody significantly decreased the HA level in 3xTg-AD
mice (Table 2) and HA vaccine decreased the urinary HA level of
3xTg-AD mice at 15 months. (HA vaccine administered to 12-
month-old 3xTg-AD mice, and three months later the urinary HA
level was measured; Table 3) Also HA vaccine specifically
decreased HA level in mice brain at 12 months old (Table 3b).
Memory Experiment
We next evaluated the hippocampus-dependent memory with
the Morris water maze task. Three-month old 3xTg-AD mice
given a vitamin B6-deficient diet exhibited significant memory
impairment compared with 3-month-old control mice (non-Tg
and Tg with a normal diet exhibited good memory performance;
Fig. 1). Notably, cotreatment with anti-HA antibody significantly
prevented vitamin B6-deficiency-induced memory impairment
(Fig. 1). This result indicates that HA can induce memory
impairment. Memory impairment induced by HA was greater in
the presence of Ab because transgenic control mice, in which there
was Ab-production and accumulation exhibited the worst memory
impairment of the three groups (Fig. 1). Amyloid alone did not
induce memory impairment despite the presence of higher levels
of both Ab-40 and -42 in the transgenic 3-month-old mice
(hemizygous + B6 deficient + anti-HA antibody) compared with
non-Tg mice [9]. Moreover, transgenic experimental mice
exhibited better memory performance than non-Tg mice.
Pathological Change
Figure 2 demonstrates immunohistochemical staining for Ab in
the amygdalar, cortical, and hippocampal cells of transgenic
control and transgenic experimental mice. Numerous stained
neurons were seen in transgenic control mice, indicating Ab
accumulation in these neurons. In contrast, transgenic experi-
mental mice (anti-HA antibody treatment) did not exhibit any
stained neurons in the hippocampus and exhibited fewer stained
neurons in the amygdala and cortex compared with transgenic
control mice (those not treated with anti-HA antibody), indicating
the inhibition of Ab accumulation. Since we observed a preventive
effect of anti-HA antibody in the acceleration of the pathogenesis
of AD in 3xTg-AD mice induced by vitamin B6-deficient food
(because 3-month-old 3xTg-AD mice with normal food intake did
not exhibit any memory impairment, but 3-month-old 3xTg-AD
mice with B6-deficient food exhibited strong memory impair-
ment), we looked for a curative effect of anti-HA antibody on the
established pathological changes in 3xTg-AD mice with AD.
3xTg-AD hemizygous 7-month-old male mice were fed vitamin
B6-deficient food for 3 weeks (control) and anti-HA antibody
Table 1. Homocysteic Acid Level in 3xTg-AD mice brain at 4
months compared with Non-Tg control mice.
Category Results P value
Hippocampus
HA level pmoles/mg
wet weight
Control 23.6369.2 (n=5)
3xTg-AD 41.2565.4 (n=4) ,0.001
Cortex
Control 20.4166.6 (n=5)
3xTg-AD 32.1664.8 (n=4) ,0.01
HA level in the brain of 3xTg-AD male mice at 4 months was measured by the
method described in Materials and Methods. Control was non-Tg male mice at
4 months.
doi:10.1371/journal.pone.0008593.t001
Table 2. HA Level in 3xTg-AD mice brain after Ingesting
Vitamin B6-Deficient food for 3 weeks.
Category Results P value
Control (n=10) 42.068.1 pmoles/mg brain
B6 deficient (n=10) 65.2615.0 pmoles/mg brain ,0.001
Anti-HA antibody
Treatment (n=10)
20.167.1 pmoles/mg brain ,0.001
Control mice: 3xTg-AD mice at 3 months and 3 weeks with normal feeding.
Control mice showed good memory performance, but B6-deficient feeding
group showed memory impairment. Whole brain was homogenized with
physiological saline and HA level was measured, after the memory task,
according to the method described in Materials and Methods.
doi:10.1371/journal.pone.0008593.t002
Table 3. HA level in 3xTg-AD mice.
A. HA Level in Urine of 3xTg-AD Mice at 15 Months (n=5)
Category Results P value
Control 22.568.5 mM
Vaccine treatment 7.869.1 mM (35% of control) ,0.001
B. HA Level in 3xTg-AD Mice Brain at 12 Months
Category Results P value
Control (n=10) 71.5620.3 pmoles/mg brain
Vaccine treatment (n=10) 30.6618.4 pmoles/mg brain (43% of
control)
,0.001
Note: A: Vaccine treatment was started at 12 months. Three months later, urine
was collected an entire day and HA level was measured. 3xTg-AD male mice
were all homozygous. HA level with vaccine treatment decreased with time,
indicating that vaccine efficacy became stronger with time.
Note: For reference, HA level in 12-month-old in 3xTg-AD male mice
were observed.
Note: B: After Morris water maze test, these mice were sacrificed and their
brains were immediately freezed in liquid nitrogen. Next, HA level was
measured with the method described in Materials and Method.
doi:10.1371/journal.pone.0008593.t003
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guide cannula.
After 3 weeks, we measured memory performance in the Morris
water maze tasks (Fig. 3), following which we evaluated the
hematoxylin-eosin and immunohistochemical staining of the brain
specimens. Control mice exhibited poor memory performance,
but experimental mice injected with anti-HA antibody exhibited
strong recovery of performance after 2 days of training, indicating
good memory performance. Also, 7-month-old 3xTg-AD mice
with normal food intake exhibited the same memory impairment;
their memory impairment was not as severe as that of 3xTg-AD
mice with vitamin B6-deficient food, which indicated that vitamin
B6-deficient food accelerated memory impairment (data not
shown here). Consistent with the results of the memory
performance task, control mice accumulated Ab in their neuronal
cells in cortex, while experimental mice accumulated less Ab than
that of control mice. The result (data not shown) was the same as
that shown in Fig. 2. Hippocampal volume was smaller in control
mice compared with non-Tg hippocampal volume, but it
recovered in the experimental group (Table 4; Fig. 4), which
suggests that the control hippocampus showed neurodegeneration
but the experimental mice may exhibit neurogenesis of hippo-
campus. It has recently been reported that the anti-pain effect
induced neurogenesis of hippocampus [11]; on the basis of this
report, we examined the anti-pain effect of HA vaccine on 21-
month-old 3xTg-AD mice. Their tails were clipped (pain source)
with a tiny metal clipper and they turned back to take off this
clipper. The time they took to turn back to take off this clipper was
measured. This result is shown in Table 5. Results of Table 5
clearly show that HA vaccine provides a strong anti-pain effect.
Results (Normal Feeding for 3xTg-AD Mice)
Our results were obtained by vitamin B6-deficient feeding to
mice, which induced the vitamin B6-deficient burden on 3xTg-AD
mice. We then investigated whether the cure effect of anti-HA
antibody can be observed on 3xTg-AD mice fed with normal food.
The result is shown in Fig. 5, and as clearly seen, there is a strong
cure effect of HA vaccine in 3xTg-AD mice (12-month-old).
The Effect of HA Vaccine Showed the Same Effect as of
Anti-HA Antibody
We developed the HA vaccine according to the anti-HA
antibody procedure described in Material and methods. The effect
of HA vaccine on memory impairment in 12-month-old 3xTg-AD
mice is shown in Fig. 5. HA vaccine has a strong cure effect on
memory impairment, which is the same as that of the anti-HA
antibody.
Discussion
We demonstrated the specificity of anti-HA antibody or HA
vaccine to destroy HA. From Tables 2 and 3, it is clearly observed
that anti-HA antibody and HA vaccine destroy HA in brain or
urine, which indicates a decreased level of HA in brain and urine.
B6-deficient food induces an increase in homocysteine, homocys-
teine sulfinic acid, and HA levels [10]. Recently, MacMahon et al.
observed that lowering homocysteine with B vitamins did not
improve cognitive performance [12] and that treating homocys-
teine levels should not be a focus of AD prevention. Homocysteine
sulfinic acid is formed by the peroxidation of homocysteine [13],
following which the latter does not play a role in the pathogenesis
Figure 1. Long-Term Memory Test in the Morris Water Maze task. Non-transgenic mice had an average score of 3 mice each day.
Hemizygous transgenic control (hemizygous + B6 deficient) mice had an average score of 3 transgenic control mice each day. Transgenic
experimental (hemizygous + B6 deficient + anti-HA antibody) mice had an average score of 3 transgenic experimental mice each day. 3xTg-AD mice
were aged 3 months and 3 weeks. Statistically significant difference was observed after 2 trial days between hemizygous + B6 deficient and
hemizygous + B6 deficient + antibody (P,0.001) and after 3 trial days between hemizygous + B6 deficient and hemizygous + B6 deficient + antibody
(P,0.05).
doi:10.1371/journal.pone.0008593.g001
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contribute to the disease pathogenesis of AD. Finally, because
HA is formed from homocysteine and methionine [13], it may
accelerate the pathogenesis of AD.
The results of our transgenic experiments confirmed that anti-
HA antibody suppressed memory impairment induced by B6-
deficient food. This hypothesis is supported by our data suggesting
that higher levels of HA are present in 3xTg-AD homozygous
mice compared with non-Tg mice (Table 1). Also, Table 2 shows
the increased level of HA induced by vitamin B6-deficient feeding.
The increased HA level was decreased by anti-HA antibody,
which indicates that anti-HA antibody actually decreases the HA
level. It is reported that HA itself has a neurodegenerative effect in
immature rat [14]. Then why did the HA level increase in 3xTg-
AD mice? We previously observed the production of HA by
cystathionine-b-synthase (CBS) in the presence of calcium and
peroxides such as lipid peroxides (unpublished observation). These
observations suggest that 3xTg-AD mice exhibit the activated gene
of presenilin, which induced the calcium level [18]. 3xTg-AD mice
exhibited the increased HA level (Table 1), and CBS is a calcium-
dependent enzyme [15]. 3xTg-AD model mice exhibit the
activated CBS activity, which induced the increased HA level.
Figure 1 shows that memory impairment induced by HA is
stronger in the presence of Ab. However, Ab itself does not induce
memory impairment because transgenic experimental mice, who
had higher levels of Ab-40 and 242 display better memory
performance than non-Tg mice. Recently, it has been reported
that amyloid oligomers induce long-term potentiation suppression
through the action of NMDA [17]; this finding supports our
observations. Our observations indicate that anti-HA antibody can
bring about normal recovery in AD. It can therefore be concluded
that HA is a true etiological agent for AD. Our hypothesis that HA
accelerated the pathogenesis of AD was confirmed by the
immunohistochemical observations. Ab accumulated in hippo-
campal neurons in the transgenic control group but not in the
transgenic experimental group. The curative effect of anti-HA
antibody was so strong that a substantive recovery in memory
performance tasks was observed. HA induced memory impair-
ment in our study and this impairment was greater in the presence
of Ab (Fig. 1), i.e., even if Ab were to be decreased, HA would still
be present in the affected brain tissue. Our findings on anti-HA
antibody treatment in transgenic mice demonstrate that the
toxicity of HA is decreased and neurodegeneration is inhibited
following which hippocampus volume increased, suggesting that
neurogenesis may occur (Table 4).
Figure 3. Curative Effect of Anti-HA Antibody as shown by
Long-Term Memory Performance. Seven-month-old male 3xTg-AD
homozygous mice mice fed B6-deficient food for 3 weeks served as the
control. Experimental mice were treated with anti-HA antibody every 3
days; antibody (100-fold dilution) was injected into the brain as
described in Materials and Methods. The figure shows average data for
five male mice. To demonstrate the strong curative effect of the
antibody, for comparison we show the results for 2-month-old
hemizygous male mice, whose memory performance was normal.
Statistically significant difference was observed after 2 trial days
(P,0.001). However after 3 trial days, a statistically significant difference
was not observed (
*P,0.001). The difference between control and
experiment mice (P,0.01). The difference between experimental mice
and 7-month-old mice with normal food (n=5).
doi:10.1371/journal.pone.0008593.g003
Figure 2. Immunohistochemical observations of Amygdalar,
Cortical, and Hippocampal Neurons. Anti-HA antibody was diluted
100-fold. Immunohistochemical observations were repeated thrice and
each observation gave the same result. Ten homozygous transgenic 3-
month-old mice were fed B6-deficient food for 3 weeks. Transgenic
experimental mice were injected with anti-HA antibody every 3 days.
For details, see Materials and Methods. CTL, transgenic control mice; Ex,
transgenic experimental mice.
doi:10.1371/journal.pone.0008593.g002
Table 4. The comparison of hippocampus major axis length
between control and experiment.
Category Results Average P value
Control 9, 8.8, 7.8, 9 8.2 (cm) 8.660.5
Experiment 9.6, 10.1, 9.6, 10.3 (cm) 9.960.4 ,0.01
Control: 7 month-old hemizygous + B6 deficient.
Experimental: 7 month-old hemizygous male +B6 deficient + anti-HA antibody.
5 different sections were observed and its major axis was measured.
Average (n=2) is shown.
Non-Tg control showed Hippocampal major axis of 1060.5 cm.
doi:10.1371/journal.pone.0008593.t004
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antibody) induced neurogenesis. We are interested in the finding
that the anti-pain effect induced the neurogenesis of hippocampus
[10]. Results show the strong anti-pain effect of HA vaccine
(Table 5), which suggests that HA vaccine (anti-HA antibody)
induced the neurogenesis of hippocampus; this suggestion is
consistent with our observation that the hippocampal volume of
the experimental mice is larger than that of the control mice. This
led to the recovery of memory performance to a normal state. It
has been recently reported that NMDA antagonists such as MK-
801 induce neurogenesis in the dentate gyrus of the hippocampus
[16] and that HA is an agonist of the NMDA receptor [2]. Then
anti-HA antibody and HA vaccine also may induce neurogenesis
according to the observation of Qu K et al. [15]
In conclusion, (i) HA accelerates pathological changes in AD;
and (ii) HA toxicity decreases with anti-HA antibody, which
induces strong neurogenesis in the hippocampus, resulting in
marked recovery of memory performance. Our hypothesis is also
supported by the observation that anti-HA antibodies induced
marked recovery in 7-month-old hemizygous mice However,
recovery was observed on the second trial day and not the third
trial day. This observation could be probably induced by the fact
that the control hemizygous mice did not impair partially their
memory ability at 7 months old and that control mice exhibited
partial good memory performance on the third trial day. We
should note the cure effect of anti-HA antibody or HA vaccine on
memory impairment of 3xTg-AD mice. Homozygous 3xTg-AD
mice exhibited complete memory impairment at 12 months old
with normal food intake (Fig. 5). HA vaccine immunized
homozygous male 3xTg-AD mice at 12 months and their memory
performance exhibited complete recovery compared with normal
2-month-old mice.
This is the first study, to our knowledge, to demonstrate marked
recovery from AD induced by treatment with anti-HA antibody or
HA vaccine. Our findings prove the strong curative effect of anti-
HA antibody treatment and HA vaccine and support the idea that
HA is a true etiological agent and an accelerator in the
Table 5. Time taken to turn back and take off the clipper.
Category Results (sec) P value
Control 28.562 s (n=5)
Vaccine treatment 5668 s (n=5) ,0.001
Mice tails were clipped by a tiny metal clipper and the time taken by the mice
to turn back and take off these clippers was measured. 3xTg-AD male mice
were 18-month-old. Vaccine treatment was started at 12 months. 3xTg-AD male
mice were all homozygous.
doi:10.1371/journal.pone.0008593.t005
Figure 5. The Effect on Memory Performance of HA Vaccine on
Normal Feeding of 3xTg-AD Male Mice. Mice were 12 months old.
Memory performance was measured via the Morris water experiment
described in Materials and Methods. Statistically significant difference
was observed on the third, fourth, and fifth trial days (P,0.001). 3xTg-
AD male mice were all homozygous (n=15).
doi:10.1371/journal.pone.0008593.g005
Figure 4. Hematoxylin-Eosin Staining of Cortical and Hippocampal Neurons in Control and Experimental Groups. Mice were treated
the same as those shown in Fig. 3.
doi:10.1371/journal.pone.0008593.g004
Homocysteic Acid Vaccine
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deficient burden 3xTg-AD mice to have HA pathogen artificially.
We thus needed to investigate whether the effect of anti-HA
antibody or HA vaccine could be observed in the normal feeding
of 3xTg-AD mice. The result shows clearly the strong cure effect of
anti-HA antibody and HA vaccine in the normal feeding of 3xTg-
AD mice (12-month-old; Fig. 5).
But how does HA induce neurodegeneration? HA affects the
two pathophysiological hallmarks of AD and may be involved in
its etiology. Moreover, HA itself can induce neurodegeneration at
a higher level with no amyloid [4], and the HA toxicity is induced
by calcium influx [17] or by mitochondrial inhibition [5] or
oxidative stress [4].
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